MedTrace Logo

Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

NCT04232774 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-03-27

No results posted yet for this study

Summary

The study is to assess the safety and feasibility of chemical denervation of multiple artery beds for the treatment of Type 2 diabetes (T2DM) and its comorbidities.

Conditions

  • Type 2 Diabetes Mellitus With Circulatory Complciation

Interventions

DEVICE

The Neurotronic arterial ablation catheter

a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.

Sponsors & Collaborators

  • Libra Medical

    collaborator OTHER

  • Neurotronic, Inc.

    lead INDUSTRY

Principal Investigators

  • John Chen · Neurotronic, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2023-01-17
Completion
2023-01-17

Countries

  • Paraguay

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232774 on ClinicalTrials.gov